What forty months of retatrutide trials have measured

The plain-English primer

Retatrutide is an investigational drug (meaning it has not been approved) developed by Eli Lilly under the internal designation LY3437943. It is built to activate three hormone receptors at once: GLP-1 (appetite and insulin), GIP (insulin and fat storage), and glucagon (energy burning and liver fat clearance). Researchers call it a triple agonist or triagonist because it acts on three targets instead of the one or two targeted by earlier drugs in this class. Clinical testing began with a small Phase 1 safety study in 2019, progressed to larger Phase 2 efficacy trials published in 2022 and 2023, and is now in large Phase 3 trials under the TRIUMPH brand name. The headline number from Phase 2: a mean body-weight reduction of 24.2 percent over 48 weeks in adults with obesity ^[1]. Phase 3 results are not yet published.

Phase 1b: pharmacokinetics and first-in-human safety

The first-in-human study (NCT04143802) established that retatrutide has a plasma half-life of approximately six days — the pharmacokinetic basis for once-weekly dosing ^[11]. The Phase 1b multiple-ascending-dose trial enrolled 72 adults with type 2 diabetes across five dose cohorts (0.5, 1.5, 3, 3/6, and 3/6/9/12 mg subcutaneous once weekly for 12 weeks) ^[4]. At the highest-dose cohort, placebo-adjusted weight loss reached −8.96 kg (90% CI −11.16 to −6.75) over 12 weeks and daily glucose fell by −2.8 mmol/L at 3 mg ^[4]. Treatment-emergent adverse events occurred in 63 percent of participants and were predominantly gastrointestinal. The safety profile was judged acceptable and the program advanced to Phase 2.

Phase 2 obesity trial: the −24.2% headline

The pivotal Phase 2 obesity trial enrolled 338 adults with obesity (BMI ≥30 or ≥27 with comorbidity) and randomized them to once-weekly subcutaneous retatrutide at 1, 4, 8, or 12 mg versus placebo for 48 weeks ^[1]. Mean body-weight change at 48 weeks was −24.2 percent at 12 mg versus −2.1 percent on placebo — the largest weight-loss signal yet recorded for a pharmacological agent at this stage of development ^[1]. Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) were dose-related and were the most common reason for discontinuation (18 percent at the highest dose). A dose-dependent heart-rate increase of approximately 5–7 bpm was also observed, peaking around 24 weeks. No severe hypoglycemia occurred.

A 2025 Biomolecules review of the Phase 1/2 dataset characterizes the up-to-24 percent weight loss as a step-change versus prior single- and dual-agonist incretin therapies, attributing the additional effect to glucagon-receptor-driven thermogenesis ^[6].

Phase 2 type 2 diabetes trial

A parallel 36-week Phase 2 trial enrolled 281 adults with type 2 diabetes (HbA1c inadequately controlled with diet and exercise, randomized to once-weekly retatrutide 0.5–12 mg with stepwise escalation versus placebo and active control) ^[2]. At 12 mg, HbA1c fell −2.02 percent versus −0.01 percent with placebo at 24 weeks; body weight fell −16.94 percent versus −3.00 percent with placebo at 36 weeks ^[2]. Mild-to-moderate GI adverse events occurred in 35 percent of participants. No severe hypoglycemia and no deaths were recorded. The 2026 TRANSCEND-T2D-1 Phase 3 trial confirmed these findings: retatrutide significantly improved glycemic control and reduced body weight as monotherapy in type 2 diabetes, with adverse events predominantly mild-to-moderate gastrointestinal and no severe hypoglycemia ^[12].

MASLD substudy: liver fat clearance

A Phase 2 substudy enrolled 98 participants with obesity or overweight and MASLD (metabolic dysfunction-associated steatotic liver disease — formerly called NAFLD) with liver-fat content ≥10 percent on MRI-PDFF (magnetic resonance imaging proton density fat fraction, a non-invasive measure of liver fat) ^[5]. At 24 weeks, relative liver-fat change was −42.9 percent (1 mg), −57.0 percent (4 mg), −81.4 percent (8 mg), and −82.4 percent (12 mg) versus +0.3 percent on placebo ^[5]. At 12 mg, 86 percent of participants reached normal liver-fat levels (<5 percent) by 24 weeks, with reductions sustained to −86.0 percent at 48 weeks ^[5]. No type 2 diabetes was present in this cohort; the finding is independent of blood-sugar effects.

Structural mechanism: cryo-EM evidence

In 2024, cryo-electron microscopy resolved retatrutide bound simultaneously to GLP-1R, GIPR, and GCGR ^[3]. The structures confirm triple-agonist engagement: relative potency was approximately 0.4x native GLP-1 at GLP-1R, 8.9x native GIP at GIPR, and 0.3x native glucagon at GCGR ^[3]. The ECL1 (extracellular loop 1) region adopts a rigid alpha-helix in GLP-1R and GCGR but a flexible loop in GIPR — a structural difference that appears to govern GIPR's higher selectivity in the retatrutide interaction ^[3]. A 2026 IUPHAR review of glucagon receptor agonism in the triple-agonist context notes that GCGR contribution to durability of weight loss remains to be confirmed in long-term outcomes trials ^[13].

The TRIUMPH Phase 3 program

Four large Phase 3 trials are ongoing under the TRIUMPH umbrella. TRIUMPH-1 (NCT05929066) is the pivotal obesity efficacy and safety trial ^[7]. TRIUMPH-3 (NCT05882045) adds an obesity-plus-established-cardiovascular-disease cohort ^[8]. A dedicated cardiovascular and kidney outcomes trial (NCT06383390) examines long-term MACE, arrhythmia burden, and renal function ^[9]. A head-to-head active-comparator trial (NCT06662383) directly compares retatrutide with tirzepatide (a dual GIP/GLP-1 agonist) — the first published direct comparison of these agents ^[10]. None of these trials has reported primary outcome results as of mid-2026. A 2024 Clinical Diabetes profile describes retatrutide as the first triple agonist developed for anti-obesity therapy, noting the Phase 3 program as the definitive evidence frontier ^[14].

A 2024 Diabetes Care review of GLP-1 medicine efficacy and safety highlights retatrutide's unique pharmacokinetic and pharmacodynamic profile via triple receptor activation, and flags GI motility and anesthesia safety implications as active clinical questions ^[15].